Amanda Kile, DO
Endocrinology, Diabetes & Metabolism · Seymour, INNPI 1255726295
Payments from drug & device makers
Across 473 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$850
- Dexcom, Inc.$774
- Corcept Therapeutics$490
- Medtronic$469
- AstraZeneca$384
- plus $3K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,246 |
| Lilly USA, LLC | 56 | $850 |
| Dexcom, Inc. | 72 | $774 |
| Corcept Therapeutics | 24 | $490 |
| Medtronic(2 entities) | 18 | $469 |
| AstraZeneca(2 entities) | 22 | $384 |
| Novartis | 19 | $339 |
| Radius Health, Inc. | 20 | $323 |
| Xeris Pharmaceuticals, Inc. | 18 | $306 |
| Amgen(2 entities) | 13 | $237 |
| Insulet Corporation | 11 | $221 |
| Boehringer Ingelheim | 13 | $209 |
| Bayer | 14 | $207 |
| AbbVie | 12 | $199 |
| Mannkind Corporation | 8 | $189 |
| Abbott | 11 | $158 |
| Recordati_rare_diseases_inc. | 8 | $152 |
| Sanofi-aventis U.S. LLC | 7 | $129 |
| Lifescan, Inc. | 8 | $111 |
| Amarin Pharma, Inc. | 6 | $107 |
| Cequr Corporation | 2 | $101 |
| IBSA Pharma Inc. | 3 | $49 |
| Sequel Med Tech, LLC | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $33 |
| GSK | 2 | $30 |
| Halozyme Inc | 2 | $28 |
| BD | 1 | $25 |
| Averitas Pharma Inc. | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$7,656 in reported general payments places this provider in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Seymour
- Emily VeenemanSeymour$583K
- Kristen GilbertSeymour$10K
- Carmella Evans-MolinaIndianapolis$6.3M
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Sana MeahMunster$829K
- James MaloneIndianapolis$822K
- Erica KretchmanRichmond$636K
- Cary MariashIndianapolis$435K
- Marian KirkmanIndianapolis$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.